Logo

Lilly's Mounjaro (tirzepatide) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes

Share this

Lilly's Mounjaro (tirzepatide) Receives the US FDA’s Approval for the Treatment of Adults with Type 2 Diabetes

Shots:

  • The approval was based on the P-III (SURPASS) program that consists of (SURPASS-1/2/3/4/5) evaluating Mounjaro (5/10/15mg) as monothx. & as an add-on therapy vs Semaglutide, insulin glargine & insulin degludec in patients with T2D. The therapy is expected to be available in the US in the coming wks.
  • The results showed avg. A1C reductions b/w 1.8% & 2.1% for Mounjaro 5mg & b/w 1.7% & 2.4% for 10 & 15mg dose while greater weight reductions in a 2EPs in all studies
  • Tirzepatide is under regulatory review in the EU, Japan & multiple other countries. The company will engage with insurers, health systems & providers to offer patients access to Mounjaro & plans to offer a Mounjaro savings card to qualified patients

Ref: Lilly | Image: Lilly 

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions